



SOFTWARE TOOL ARTICLE

REVISED Sarek: A portable workflow for whole-genome sequencing analysis of germline and somatic variants [version 2; peer review: 2 approved]

Maxime Garcia ^{1*}, Szilveszter Juhos^{1-3*}, Malin Larsson⁴, Pall I. Olason³, Marcel Martin ⁵, Jesper Eisfeldt ⁶, Sebastian DiLorenzo⁷, Johanna Sandgren¹, Teresita Díaz De Ståhl¹, Philip Ewels ², Valtteri Wirta⁸, Monica Nistér ¹, Max Käller⁹, Björn Nystedt ³

¹Department of Oncology-Pathology, Karolinska Institutet, J5:30 BioClinicum, Visionsgatan 4, Karolinska University Hospital at Solna, Solna, 17164, Sweden

²Department of Biochemistry and Biophysics, Science for Life Laboratory, Stockholm University, Box 1031, Solna, 17121, Sweden

³Department of Cell and Molecular Biology, National Bioinformatics Infrastructure Sweden, Science for Life Laboratory, Uppsala University, Husargatan 3, Uppsala, 752 37, Sweden

⁴Department of Physics, Chemistry and Biology, National Bioinformatics Infrastructure Sweden, Science for Life Laboratory, Linköping University, Linköping, 58183, Sweden

⁵Department of Biochemistry and Biophysics, National Bioinformatics Infrastructure Sweden, Science for Life Laboratory, Stockholm University, Box 1031, Solna, 17121, Sweden

⁶Clinical Genetics, Department of Molecular Medicine and Surgery, Karolinska Institutet, MMK L1:00, Karolinska University Hospital at Solna, Stockholm, 171 76, Sweden

⁷Department of Medical Sciences, National Bioinformatics Infrastructure Sweden, Science for Life Laboratory, Uppsala University, Husargatan 3, Uppsala, 752 37, Sweden

⁸Department of Microbiology, Tumor and Cell Biology, Clinical Genomics Facility, Science for Life Laboratory, Karolinska Institutet, Box 1031, Solna, 171 21, Sweden

⁹School of Engineering Sciences in Chemistry, Biotechnology and Health, Science for Life Laboratory, KTH Royal Institute of Technology, Box 1031, Solna, 17121, Sweden

* Equal contributors

v2 First published: 29 Jan 2020, 9:63
<https://doi.org/10.12688/f1000research.16665.1>

Latest published: 04 Sep 2020, 9:63
<https://doi.org/10.12688/f1000research.16665.2>

Abstract

Whole-genome sequencing (WGS) is a fundamental technology for research to advance precision medicine, but the limited availability of portable and user-friendly workflows for WGS analyses poses a major challenge for many research groups and hampers scientific progress. Here we present Sarek, an open-source workflow to detect germline variants and somatic mutations based on sequencing data from WGS, whole-exome sequencing (WES), or gene panels. Sarek features (i) easy installation, (ii) robust portability across different computer environments, (iii) comprehensive documentation, (iv) transparent and easy-to-read code, and (v) extensive quality metrics reporting.

Open Peer Review

Approval Status

1

2

version 2

(revision)
04 Sep 2020

version 1

29 Jan 2020



view



view


1. Tony Håndstad, Oslo University Hospital,

Sarek is implemented in the Nextflow workflow language and supports both Docker and Singularity containers as well as Conda environments, making it ideal for easy deployment on any POSIX-compatible computers and cloud compute environments. Sarek follows the GATK best-practice recommendations for read alignment and pre-processing, and includes a wide range of software for the identification and annotation of germline and somatic single-nucleotide variants, insertion and deletion variants, structural variants, tumour sample purity, and variations in ploidy and copy number. Sarek offers easy, efficient, and reproducible WGS analyses, and can readily be used both as a production workflow at sequencing facilities and as a powerful stand-alone tool for individual research groups. The Sarek source code, documentation and installation instructions are freely available at <https://github.com/nf-core/sarek> and at <https://nf-co.re/sarek/>.

Keywords

Analysis workflow, Whole Genome Sequencing, Germline variants, Somatic variants, Cancer

Oslo, Norway

2. **Esa Pitkänen** , University of Helsinki, Helsinki, Finland

University of Helsinki, Helsinki, Finland

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: Björn Nystedt (bjorn.nystedt@scilifelab.se)

Author roles: **Garcia M:** Conceptualization, Methodology, Project Administration, Software, Validation, Writing – Review & Editing; **Juhos S:** Conceptualization, Methodology, Project Administration, Software, Validation, Writing – Review & Editing; **Larsson M:** Conceptualization, Methodology, Software, Validation, Writing – Review & Editing; **Olason PI:** Conceptualization, Methodology, Software, Validation, Writing – Review & Editing; **Martin M:** Software, Validation, Writing – Review & Editing; **Eisfeldt J:** Software, Validation, Writing – Review & Editing; **DiLorenzo S:** Software, Validation, Writing – Review & Editing; **Sandgren J:** Validation, Writing – Review & Editing; **Diaz De Ståhl T:** Validation, Writing – Review & Editing; **Ewels P:** Software, Supervision, Writing – Review & Editing; **Wirta V:** Conceptualization, Writing – Review & Editing; **Nistér M:** Conceptualization, Supervision, Writing – Review & Editing; **Käller M:** Conceptualization, Project Administration, Supervision, Writing – Review & Editing; **Nystedt B:** Conceptualization, Project Administration, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This study was supported by the Swedish Research Council (NGI: 2017-00630, NBIS: 2017-00656), the Swedish Childhood Cancer Fund (The Swedish Childhood Tumor Biobank (BTB): BB2017-0001; BB2018-0001; BB2019-0001), and the Knut and Alice Wallenberg Foundation (KAW 2014.0278).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2020 Garcia M *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Garcia M, Juhos S, Larsson M *et al.* **Sarek: A portable workflow for whole-genome sequencing analysis of germline and somatic variants [version 2; peer review: 2 approved]** F1000Research 2020, 9:63 <https://doi.org/10.12688/f1000research.16665.2>

First published: 29 Jan 2020, 9:63 <https://doi.org/10.12688/f1000research.16665.1>

REVISED Amendments from Version 1

This version is a minor revision and improvement of the already accepted manuscript, based on the comments from the two reviewers.

The main change is the inclusion of accuracy measures for germline variants based on the Genome In a Bottle HG001 gold standard dataset, presented in the text and in the new [Table 4](#).

In addition, we have also added information about which tools are used for each type of variant calling in the revised [Table 1](#). Other edits to the text are minor clarifications of i) the selection of the included software, ii) the usage of the “-profile” parameter, iii) the yet limited benchmarking of exome sequencing data, iv) the availability of a small test dataset, v) the user responsibility to adjust the downstream filtering of variants, vi) how Docker, Singularity and Conda environments are provided, and vii) the workflow error handling.

Any further responses from the reviewers can be found at the end of the article

Introduction

Whole-genome sequencing (WGS) and whole-exome sequencing (WES) technologies opens up new avenues for research and for clinical applications, with many large initiatives launched worldwide. While much effort has been invested in novel sequencing analysis software, the importance of providing and maintaining workflows to combine software in an efficient and reproducible manner has been underestimated and too few resources are typically dedicated to address this issue. This is of particular importance for somatic variant analysis and especially for analysis of complex cancer genomes, where a combination of tools is still required for optimal sensitivity and specificity and to detect various types of gene mutations and other abnormalities ([Alioto et al., 2015](#)). Some encouraging solutions have been presented in recent years, including [SeqMule](#) ([Guo et al., 2015](#)), [SpeedSeq](#) ([Chiang et al., 2015](#)), [Bcbio-nextgen](#), and [DNAP](#) ([Causey et al., 2018](#)). While all of the above represent commendable and important efforts, we have not found any workflow solution that in our opinion fulfils all of the following important user aspects: (i) easy installation, (ii) robust portability across different compute environments, (iii) comprehensive documentation, (iv) transparent and easy-to-read code, and (v) extensive quality metrics reporting. Here we present Sarek, an easy-to-install community-maintained workflow, offering a complete and scalable solution for germline and somatic variant detection, annotation and quality control. Sarek supports several reference genomes and can handle data from WGS, WES and gene panels, and is intended to be used both as a production workflow at core facilities and as a stand-alone tool for individual research groups. By using Docker or Singularity containers, Sarek installs easily on all POSIX compatible systems such as Linux and Mac OS X and is designed to work on compute environments dedicated to handle sensitive personal data without direct internet access—a situation expected to become increasingly common with growing data security awareness.

Methods**Operation: Workflow overview and software**

Sarek offers a portable workflow for germline and somatic variant detection, annotation and quality control based on WGS, WES or gene panel data, using a range of state-of-the-art software and data resources in the field ([Table 1](#), [Figure 1](#)). In the pre-processing step, sequence reads are aligned to the reference genome with BWA-MEM ([Li, 2013](#)), followed by deduplication and recalibration with GATK ([McKenna et al., 2010](#)). For germline samples, single-nucleotide variants and small insertion/deletions are detected with HaplotypeCaller ([McKenna et al., 2010](#)) and Strelka2 ([Kim et al., 2018](#)), and structural variations are detected with Manta ([Chen et al., 2016](#)) and TIDDIT ([Eisfeldt et al., 2017](#)). For somatic samples, somatic single-base mutations (SSM) and small somatic insertion/deletion mutations (SIM) are detected by GATK4 Mutect2 ([Cibulskis et al., 2013](#)) and Strelka2 ([Kim et al., 2018](#)). Somatic structural variants (including copy-number variation), as well as ploidy and sample purity are detected by Manta ([Chen et al., 2016](#)), ASCAT ([Van Loo et al., 2010](#)), and Control-FREEC ([Boeva et al., 2012](#)). All variants are annotated for potential functional effects with snpEff ([Cingolani et al., 2012](#)) and VEP ([McLaren et al., 2016](#)). Importantly, Sarek also generates a wide range of quality control metrics using [FastQC](#), [QualiMap](#) ([Okonechnikov et al., 2016](#)), [BCFtools](#) ([Li, 2011](#)), [Samtools](#) ([Li et al., 2009](#)), and [VCFtools](#) ([Danecek et al., 2011](#)), visualized as an aggregated quality control review across samples with [MultiQC](#) ([Ewels et al., 2016](#)). All software currently included in Sarek are selected based on the criteria that they should be of high quality, well-maintained, and with robust installation and running performances. Additional alternative or complementing software will be added to Sarek in later updates, based on the input and engagement of the user community.

Portability and reproducibility

Sarek is implemented in Nextflow ([Di Tommaso et al., 2017](#)), a workflow language designed specifically for bioinformatics applications. Nextflow has a transparent design, making the Sarek code easy to read, adjust and extend. Sarek has well-functioning error reporting to diagnose e.g. software or hardware errors during a run, and incomplete runs are easily restarted from any stage in the workflow process. Compared to the Bpipe workflow language (used in for example DNAP), Nextflow offers superior support for different execution environments, like Slurm, Sun Grid Engine, LSF and Kubernetes, and includes native support for cloud compute environments including Google Cloud and AWS. Support for [AWS batch](#) gives the possibility to easily distribute thousands of batch jobs on Amazon Web Services. Sarek is part of a rapidly growing community effort of well documented and community-tested [Nextflow pipelines](#), and adheres to the nf-core portability and documentation guidelines ([Ewels et al., 2019](#)). To facilitate easy installation and to ensure reproducibility, all Sarek required tools are installed in Conda, and then pushed to DockerHub (<https://hub.docker.com/>), making Sarek and all its dependencies directly accessible from a Conda environment, or as [Docker](#) or

Table 1. Software required and implemented in Sarek. A list of all the software required and currently implemented in Sarek. All analysis and quality metrics software are installed automatically when Sarek is launched. P, Preprocessing; G, Germline; S, Somatic; snv, Single-nucleotide variants and small indels; sv, Structural variants; pp, Ploidy and sample purity; a, Annotation.

Software/Resource	Analyses	Availability
Required software		
Nextflow		https://www.nextflow.io/index.html
Docker, Singularity or Conda		https://www.docker.com/ , https://sylabs.io/ , https://docs.conda.io/en/latest/
Included analysis software		
BWA-MEM	P	http://bio-bwa.sourceforge.net/
GATK4	P, G(snv)	https://software.broadinstitute.org/gatk/
Samtools	P, G(snv)	https://github.com/samtools/samtools
Strelka2	G(snv), S(snv)	https://github.com/Illumina/strelka
Manta	G(sv), S(sv)	https://github.com/Illumina/manta
TIDDIT	G(sv)	https://github.com/SciLifeLab/TIDDIT
GATK4 Mutect2	S(snv)	https://gatk.broadinstitute.org/hc/en-us/articles/360037593851-Mutect2
Freebayes	S(snv)	https://github.com/ekg/freebayes
ASCAT	S(pp)	https://github.com/Crick-CancerGenomics/ascap
Control-FREEC	S(pp)	http://boevalab.inf.ethz.ch/FREEC/
snpEff	G(a), S(a)	http://snpeff.sourceforge.net/
VEP	G(a), S(a)	http://www.ensembl.org/vep
Included quality metrics software		
MultiQC		http://multiqc.info/
FastQC		https://www.bioinformatics.babraham.ac.uk/projects/fastqc/
BamQC		https://github.com/s-andrews/BamQC
QualiMap		http://qualimap.bioinfo.cipf.es/
BCFtools		https://github.com/samtools/bcftools
VCFTools		https://vcftools.github.io/index.html

Singularity (Kurtzer *et al.*, 2017) containers. While Docker is a widely appreciated container solution, it is not always allowed at high-performance computing centers because of the involved security risks, making Singularity the preferred choice at these sites (Kurtzer *et al.*, 2017). This is of particular importance for computer environments designed for handling of sensitive personal data, where a high level of data security has to be maintained across multiple projects and users.

Implementation: equipment and resource usage

Sarek can be installed and executed on any POSIX-compatible computer system. To run a full WGS analysis, including both germline and somatic variants from a tumour/normal dataset with 90x/90x read coverage, we recommend a minimum of 16 cores on a node with 128 GB RAM, and at least 4 TB available free storage (in addition to the initial FASTQ files) in the input/output working directory. Of this, about 1.4 TB will be allocated for BAM files, annotated VCF files and CNV files, but excluding GVCF files (Table 2). At the end of the run, 2.3 TB temporary

data can be removed, unless the user plans to perform re-runs from intermediate processing states. Many processes are distributed across cores by dividing the genome into smaller chunks, each being handled as a separate core job, with all the results being merged and sorted in a final step. Some of the used software are parallelized by design, while for others Sarek uses a scatter-gather approach to efficiently distribute the processing load across CPU cores and reduce the wall clock runtime.

Installation and testing

Sarek is run from a computer system with a local installation of Nextflow and support for either Conda environments, Docker or Singularity containers. Nextflow can automatically fetch the Sarek source code from GitHub. All software dependencies are encapsulated in Docker or Singularity containers which are downloaded from [Docker Hub](#), or built in a new Conda environment using Bioconda (Grüning *et al.*, 2018). As such, cumbersome software installations by the user are completely avoided. Configuration files allow tailoring to specific




Figure 1. Schematic overview of the Sarek workflow for analysis of germline and somatic variants. A schematic overview including some of the main analysis software implemented in the Sarek workflow. A more comprehensive list of the currently implemented software is given in [Table 1](#).

user needs. Sarek comes with a small test dataset and a suite of tests to verify the installation. This is also used for Continuous Integration testing with [GitHub Actions](#).

Results

To test performance in terms of resource usage and biological results, Sarek was run on a medulloblastoma WGS tumour/normal dataset from a sample with high tumour cell content (~98%), and with a curated “Gold Set” of verified somatic mutations from a previous benchmark study ([Alioto et al., 2015](#)). In line with the above benchmark study, Sarek (version 2.5.2) was executed with WGS germline and somatic variant calling using a 90X/90X tumour/normal dataset (accession number EGAD00001001859, read sets EGAR00001387019-24 and EGAR00001387025-32). Runs were performed on a single 48-thread node with a local direct attached storage (DAS): A Dell PowerEdge R740 server, with two Intel Xeon Gold 6126 with a total of 24 cores (48 threads) CPUs, 756 GB memory, and 100 TB SCv3020 Compellent Storage. The complete Sarek run including preprocessing followed by both germline and somatic variant calling and annotation took 48 hours and 21 minutes, and required about three times more storage than the original input data ([Table 2](#)). Notably, the complete Sarek run was executed by a single command, with fully automated installation, execution, and efficient job distributions of the more than 15 different software tools to complete the analysis and provide quality control metrics, without any manual intervention needed during the two-day run. To ensure that the Sarek output was biologically sound, we calculated precision, recall and F1 statistics for the Sarek output based on the “Gold Set” of somatic single-base mutations (SSM) and somatic insertion/deletion mutations (SIM) as previously defined ([Alioto et al., 2015](#)). Using the intersection of the output from the two somatic variant callers (GATK4 Mutect2 and Strelka2), Sarek provided accuracy measures for SSMs (F1 score = 0.80) and SIMs (F1 score = 0.58) in the top range of the 18 somatic variant calling procedures included in the original benchmarking study on this data set ([Table 3](#)), indicating that the workflow operates as intended. The sample purity was estimated to be 100%, as compared to 98% previously reported for this sample. For somatic structural variants and

Table 2. Sarek resource usage. Resource usage during a Sarek run on a WGS 90X/90X coverage medulloblastoma dataset on a 48-threaded computer node, starting from compressed FASTQ files. The storage resources refer to result files only. The total storage including all temporary data was 3.7 TB.

	Input data	Mapping, merging, deduplication	Quality score recalibration	Variant calling, annotation	Total
Storage	458 GB	530 GB	386 GB	4 GB	1378 GB
Process time		1081 CPU h	95 CPU h	614 CPU h	1790 CPU h
Wall clock time		35h 26m	3h 26m	13h 29m	48h 21m
Peak memory		119 GB	18 GB	128 GB	

GB, gigabyte; CPU, central processing unit; h, hours; m, minutes.

Table 3. Sarek WGS somatic variant benchmarking. Summary of accuracy measures for the two somatic variant callers used in Sarek to detect somatic single-base mutations (SSMs) and somatic insertion/deletion mutations (SIMs), as well as their union and intersection.

Somatic caller	Recall	Precision	F1-score
SSM (Gold Set: n=1263)			
GATK4 Mutect2	0.80	0.45	0.58
Strelka2	0.77	0.29	0.42
Union (GATK4 Mutect2, Strelka2)	0.82	0.23	0.36
Intersection (GATK4 Mutect2, Strelka2)	0.74	0.88	0.80
Benchmark median*	0.68	0.78	0.71
SIM (Gold Set: n=347)			
GATK4 Mutect2	0.48	0.38	0.42
Strelka2	0.74	0.31	0.44
Union (GATK4 Mutect2, Strelka2)	0.77	0.25	0.38
Intersection (GATK4 Mutect2, Strelka2)	0.46	0.77	0.58
Benchmark median*	0.34	0.71	0.48

* The median accuracy measures across 18 somatic variant calling procedures as previously reported (Alioto *et al.*, 2015)

ploidy, no relevant benchmark data was available, and therefore no quantitative assessment beyond previously published results for the implemented software could be performed, but the integrity of the runs were checked by comparing the results of Manta, ASCAT, and Control-FREEC run within Sarek and as stand-alone. To benchmark Sarek on germline single-nucleotide variants and small insertions/deletions, we used 46X WGS data for the well-studied individual NA12878:HG001 (ftp://ftp-trace.ncbi.nlm.nih.gov/giab/ftp/data/NA12878/NIST_NA12878_HG001_HiSeq_300x/, read set folders 131219_D00360_005_BH814YADXX [accession number SRR2052337 - SRR2052339, SRR2052342, SRR2052345, SRR20523428], and 131219_D00360_006_AH81VLADXX [accession number SRX1049774 -SRX1049779]) and a “Gold Set” of variants from the Genomein a Bottle project (Zook *et al.*, 2019), showing overall high accuracy (Table 4).

Use case

Sarek has been extensively tested and applied on various WGS datasets, including thousands of samples for germline variant analyses, and hundreds of paired tumour/normal samples for somatic mutation analyses. In addition, Sarek has also been adapted to run on WES data and gene panels, and has been reported to work well in pilot user projects, although no systematic testing has yet been performed on such data. Below we present a standard use case with a tumour/normal WGS dataset as input, running both germline and somatic variant analyses.

Input data

For a somatic variant analysis, the user should provide the sequencing FASTQ files from both tumour and normal control

tissue from the same individual, described in a tab-delimited TSV file (here: *samples.tsv*). Each line of the TSV file contains information about a sequence data file, including: The identifier of the individual, the gender (XX or XY), the status of the sample (0 for Normal or 1 for Tumour), the identifier of the sample, the sequencing lane (if samples are multiplexed across multiple lanes), and the paths to the FASTQ file of the first and second read in the read-pair. Relapse samples from the same individual are also supported.

Running sarek on WGS data with singularity containers

Running Sarek with Singularity container on a computer system supporting Java 8 requires only installation of Nextflow and Singularity. A full analysis run starting from FASTQ files including mapping, recalibration, variant calling and annotation, as well as generating a full QC report can be invoked by a single Nextflow command:

```
> nextflow run nf-core/sarek -r 2.5.2 -profile singularity --input samples.tsv --tools Mute ct2,Strelka,Manta,TIDDIT,ASCAT,ControlFREEC, snpEff,VEP
```

Nextflow will recognize the workflow name and will download the specified version (2.5.2) of the pipeline from GitHub, including the corresponding container, as well as fetching the required reference files from [AWS-iGenomes](#). The default reference genome is human GRCh38, but Sarek also supports GRCh37 and nearly 30 other genomes directly accessible from iGenomes. Alternatively, users can manually supply Sarek with other reference genomes. Non-default parameters and links to local reference files are handled in accordance with nf-core

Table 4. Sarek WGS germline variant benchmarking. Summary of accuracy measures for the two variant callers used in Sarek to detect germline single-nucleotide variants (SNVs) and germline insertion/deletion variants (INDELs), as well as their union and intersection.

Germline caller	Recall	Precision	F1-score
SNV (Gold Set: n=3088156)			
GATK4 HaplotypeCaller	0.93	1.00	0.96
Strelka2	0.98	1.00	0.99
Union (GATK4 HaplotypeCaller, Strelka2)	0.99	0.94	0.96
Intersection (GATK4 HaplotypeCaller, Strelka2)	0.93	1.00	0.96
INDEL (Gold Set: n=530423)			
GATK4 HaplotypeCaller	0.91	0.99	0.95
Strelka2	0.92	0.99	0.95
Union (GATK4 HaplotypeCaller, Strelka2)	0.93	0.98	0.96
Intersection (GATK4 HaplotypeCaller, Strelka2)	0.90	1.00	0.94

guidelines. User configuration profiles can be stored locally or centrally at <https://github.com/nf-core/configs>.

Output

A full Sarek run will produce a large number of output files, but the main results consist of (i) a set of annotated variants in VCF files from the various included tools for both germline and somatic variants, (ii) tumour sample purity and ploidy results for somatic samples, and (iii) a broad set of QC metrics. A detailed description of all output files is given at the [Sarek documentation pages](#). While Sarek will report variants from all callers included in the run, it is up to the user to decide how to combine and filter the results from different callers, since the optimal post-processing will depend on the particular samples and research questions at hand.

Discussion

Human WGS is transforming medical research, and provides a foundation to develop novel clinical applications and improve health care. An important aspect to harvesting the potential of WGS is however to empower the research community with adequate bioinformatics tools, and reproducible bioinformatics workflows are important drivers of scientific progress by making complex processing of large datasets feasible for a wide range of researchers. While we are highly appreciative of existing workflows for cancer and non-cancer variant detection, we argue that there is no one-size-fits-all solution and more initiatives are needed to serve the large and diverse research user community, especially for WGS data. Sarek builds on a philosophy of reasonably narrow, independent workflows, written in the domain-specific language Nextflow. In our experience, this is an effective strategy to simplify workflow maintenance at sequencing core facilities, and to allow easy deployment and modifications by individual research groups. Sarek efficiently utilizes cloud and high-performance compute clusters and installs easily across compute environments. Sarek provides

annotated VCF files, CNV reports and quality metrics for germline and cancer samples from raw FASTQ sequencing data in about 48 hours for 90X/90X WGS data (as demonstrated here), in a few hours for WES data, and within minutes for gene panels (in-house data, not presented here). It should be noted that while Sarek can substantially reduce the labor and management time of running and maintaining a large collection of software, and help users to perform quality-controlled reporting in an organized manner, careful parameter tuning, downstream variant filtering, and qualitative assessments by the user remains important. Ongoing efforts aim to develop add-on ranking and visualization modules and to efficiently extract clinically and biologically relevant findings, to help advance basic and translational research.

Conclusion

Sarek is a portable and reproducible workflow to detect germline and somatic variants from WGS, WES and gene panel data. It includes extensive analysis and quality control metrics, while still being limited to a relatively narrow scope to achieve optimal usability, functionality and transparency. Sarek is flexible with a low threshold for user modifications, and is thus well adapted to the current requirements in the research community. Thanks to its design, it installs easily and reproducibly on all POSIX compatible computer systems, including secure compute environments for sensitive personal data with indirect Internet access.

Data availability

Source data

European Genome-phenome Archive: A comprehensive assessment of somatic mutation detection in cancer using whole genome sequencing. <https://www.ebi.ac.uk/ega/datasets/EGAD00001001859>. Read sets EGAR00001387019-24 and EGAR00001387025-32 were analysed. These data are held under restricted access. Readers wishing to apply for access to the data must first

apply through the ICGC Data Access Compliance Office (<https://icgc.org/daco>) and complete the data access form. Access will be granted to those whose projects conform to the [goals and policies of ICGC](#). Help with completing the data access form is available at <https://icgc.org/daco/help-guide-section>.

Sequence Read Archive: NIST Genome in a Bottle, ~300X sequencing of HG001 (NA12878). ftp://ftp-trace.ncbi.nlm.nih.gov/giab/ftp/data/NA12878/NIST_NA12878_HG001_HiSeq_300x/, read set folders 131219_D00360_005_BH814YADXX [SRA accession number SRR2052337 - SRR2052339, SRR2052342, SRR2052345, SRR20523428], and 131219_D00360_006_AH81V-LADXX [SRA accession number SRX1049774 -SRX1049779]). These data are publicly available for direct download.

The workflow itself comes with a prebuilt profile with a complete configuration for automated testing, including links to a small test dataset.

Software availability

Sarek is available at: <https://nf-co.re/sarek>.

Source code available at: <https://github.com/nf-core/sarek>.

Archived source code at time of publication: <https://doi.org/10.5281/zenodo.3579102> (Garcia *et al.*, 2019).

License: MIT License.

Author contributions

MK, BN and MN conceived the idea for Sarek. MG and SJ led the project. MG, SJ, ML, PIO, MM, JE, and SDL designed and implemented the workflow. JS, TDS, VW, MN, BN, PE and MK performed testing and provided design feedback. MG, SJ and BN wrote the manuscript with the help from all authors.

Acknowledgements

We are grateful for the valuable input from the Oslo University Hospital bioinformatics core facility (Oslo University Hospital), the T Martinsson lab (Gothenburg University), the A–C Syvänen lab (Uppsala University), and Alex Peltzer (Quantitative Biology Center, University of Tübingen). The National Genomics Infrastructure (NGI) and Uppsala Multidisciplinary Centre for Advanced Computational Science (UPPMAX) provided computational resources. Help with graphical design was provided by Dr. Jonas Söderberg (Uppsala university).

References

- Alloto TS, Buchhalter J, Dordick S, *et al.*: **A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing.** *Nat Commun.* 2015; **6**: 10001.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Boeva V, Popova T, Bleakley K, *et al.*: **Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data.** *Bioinformatics.* 2012; **28**(3): 423–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Causey JL, Ashby C, Walker K, *et al.*: **DNAP: A Pipeline for DNA-seq Data Analysis.** *Sci Rep.* 2018; **8**(1): 6793.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Chen X, Schulz-Trieglaff O, Shaw R, *et al.*: **Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications.** *Bioinformatics.* 2016; **32**(8): 1220–1222.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Chiang C, Layer RM, Faust GG, *et al.*: **SpeedSeq: ultra-fast personal genome analysis and interpretation.** *Nat Methods.* 2015; **12**(10): 966–968.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Cibulskis K, Lawrence MS, Carter SL, *et al.*: **Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples.** *Nat Biotechnol.* 2013; **31**(3): 213–219.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Cingolani P, Platts A, Wang le L, *et al.*: **A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of *Drosophila melanogaster* strain w¹¹¹⁸; iso-2; iso-3.** *Fly (Austin).* 2012; **6**(2): 80–92.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Danecek P, Auton A, Abecasis G, *et al.*: **The variant call format and VCFtools.** *Bioinformatics.* 2011; **27**(15): 2156–2158.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Di Tommaso P, Chatzou M, Floden EW, *et al.*: **Nextflow enables reproducible computational workflows.** *Nat Biotechnol.* 2017; **35**(4): 316–319.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Eisfeldt J, Vezzi F, Olason P, *et al.*: **TIDBIT, an efficient and comprehensive structural variant caller for massive parallel sequencing data [version 2; peer review: 2 approved].** *F1000Res.* 2017; **6**: 664.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Ewels P, Magnusson M, Lundin S, *et al.*: **MultiQC: Summarize analysis results for multiple tools and samples in a single report.** *Bioinformatics.* 2016; **32**(19): 3047–3048.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Ewels PA, Peltzer A, Fillinger S, *et al.*: **nf-core: Community curated bioinformatics pipelines.** *bioRxiv.* 2019; **610741**.
[Publisher Full Text](#)
- Garcia M, Peltzer A, Alneberg J: **nf-core/sarek: Sarek 2.5.2 - Jäkkätjaskajekna (Version 2.5.2).** *Zenodo.* 2019.
<http://www.doi.org/10.5281/zenodo.3579102>
- Grüning B, Dale R, Sjödin A, *et al.*: **Bioconda: sustainable and comprehensive software distribution for the life sciences.** *Nat Methods.* 2018; **15**(7): 475–476.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Guo Y, Ding X, Shen Y, *et al.*: **SeqMule: automated pipeline for analysis of human exome/genome sequencing data.** *Sci Rep.* 2015; **5**: 14283.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Kim S, Scheffler K, Halpern AL, *et al.*: **Strelka2: fast and accurate calling of germline and somatic variants.** *Nat Methods.* 2018; **15**(8): 591–594.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Kurtzer GM, Sochat V, Bauer MW: **Singularity: Scientific containers for mobility of compute.** *PLoS One.* 2017; **12**(5): e0177459.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Li H: **A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data.** *Bioinformatics.* 2011; **27**(21): 2987–2993.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Li H: **Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM.** *arXiv 1303.3997v2.* 2013.
[Reference Source](#)

Li H, Handsaker B, Wysoker A, *et al.*: **The Sequence Alignment/Map format and SAMtools.** *Bioinformatics.* 2009; **25**(16): 2078–2079.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

McKenna A, Hanna M, Banks E, *et al.*: **The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data.** *Genome Res.* 2010; **20**(9): 1297–1303.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

McLaren W, Gil L, Hunt SE, *et al.*: **The Ensembl Variant Effect Predictor.** *Genome Biol.* 2016; **17**(1): 122.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Okonechnikov K, Conesa A, García-Alcalde F: **Qualimap 2: advanced**

multi-sample quality control for high-throughput sequencing data. *Bioinformatics.* 2016; **32**(2): 292–294.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Van Loo P, Nordgard SH, Lingjærde OC, *et al.*: **Allele-specific copy number analysis of tumors.** *Proc Natl Acad Sci U S A.* 2010; **107**(39): 16910–16915.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Zook JM, McDaniel J, Olson ND, *et al.*: **An open resource for accurately benchmarking small variant and reference calls.** *Nat Biotechnol.* 2019; **37**(5): 561–566.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status:  

Version 1

Reviewer Report 31 March 2020

<https://doi.org/10.5256/f1000research.18214.r61129>

© 2020 Pitkänen E. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Esa Pitkänen 

¹ Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland

² Applied Tumor Genomics Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland

This manuscript describes Sarek, a workflow for analyzing next-generation sequencing (NGS) data. Sarek is based on Nextflow, a popular tool for defining computational workflows. In order to process NGS data, i.e., generating annotated variant calls ready for downstream analyses, multiple complex software tools need to be executed. This is not only computationally demanding, but also labor-intensive due to operators having to install and maintain a complicated collection of software as well as diagnose failed analysis runs, often resulting in high management overhead compared to the total computation time (Yakneen and Waszak, 2020¹). Sarek aims to minimize the installation and management time overhead by building a NGS workflow on top of Nextflow, automatically installing the required software components. These software consist of some of the state-of-the-art tools in read mapping, variant calling and annotation and quality control. Sarek is a welcome addition to the toolkit of bioinformaticians looking for an NGS analysis workflow, which can be easily installed on a HPC cluster or cloud environment. The article is well-written and clear to understand. While I'm happy to recommend indexing of the manuscript also in the present form, I have a few suggestions how to improve it:

Major comments:

1. While some of the existing NGS workflows are mentioned, I would appreciate it if Sarek was compared to these approaches in more detail. Is there functionality that is currently missing from Sarek that is present in one of the other workflows?
2. Typically in NGS data analysis, a lot of time can be spent on debugging failed runs to find out whether one of the tools failed, if the data is corrupted/missing or if there was a hardware error. How does Sarek support run diagnostics and relaunching failed jobs?
3. How does Sarek combine variant calls when multiple callers are used for a variant type?

4. Somatic single nucleotide and indel variant calls from Sarek were shown to match well with a previously defined gold standard callset. No benchmark data was available for more complex somatic variants and variant calling accuracy for germline variants was not evaluated. I am interested in seeing more comprehensive tests to cover all germline and somatic variant types.
5. I would appreciate it if a minimal test dataset together with instructions and a suite of automated tests was provided with Sarek. This would make it easier for the user to test out an installation as well as raising issues in GitHub.

Minor comments:

1. How easy it is for users to modify or extend Sarek by for example adding a new variant caller to the workflow? This could be explored in more detail in text.
2. It would be good to easily see which tools are used to call and analyze each variant type. This information could be added either to Fig 1, Table 1 or both.
3. FreeBayes is included in Figure 1 but missing from Table 1.
4. The wording in "To facilitate easy installation and to ensure reproducibility, all Sarek required tools are managed in Docker or Singularity (Kurtzer et al., 2017) containers, or a Conda environment." should be clarified -- are all tools being maintained in all the three systems?
5. When running Sarek with default options, it crashes in the tool version check. It took me a while to figure out this was due to the default "-profile" argument of "standard" which seems to assume Singularity is available. It would be good to improve error messages so that it is easier to understand the underlying cause. A minimal installation and testing procedure mentioned above would help in this regard.
6. Typo: "Whole-genome sequencing (WGS) and whole-exome sequencing (WES) technologies opens..." -> "...open".

References

1. Yakneen S, Waszak SM, PCAWG Technical Working Group, Gertz M, et al.: Butler enables rapid cloud-based analysis of thousands of human genomes. *Nat Biotechnol.* 2020; **38** (3): 288-292
[PubMed Abstract](#) | [Publisher Full Text](#)

Is the rationale for developing the new software tool clearly explained?

Yes

Is the description of the software tool technically sound?

Yes

Are sufficient details of the code, methods and analysis (if applicable) provided to allow replication of the software development and its use by others?

Yes

Is sufficient information provided to allow interpretation of the expected output datasets and any results generated using the tool?

Yes

Are the conclusions about the tool and its performance adequately supported by the findings presented in the article?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Bioinformatics, cancer genetics, machine learning

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 01 Jul 2020

Björn Nystedt, National Bioinformatics Infrastructure Sweden, Science for Life Laboratory, Uppsala University, Husargatan 3, Uppsala, Sweden

We are grateful to the reviewer for the positive and constructive comments! We have uploaded a revised version of the manuscript and included updated documentation for the workflow, including adjustments and improvements as suggested by the reviewer, and as described in the detailed comments below, marked in bold.

Approved

This manuscript describes Sarek, a workflow for analyzing next-generation sequencing (NGS) data. Sarek is based on Nextflow, a popular tool for defining computational workflows. In order to process NGS data, i.e., generating annotated variant calls ready for downstream analyses, multiple complex software tools need to be executed. This is not only computationally demanding, but also labor-intensive due to operators having to install and maintain a complicated collection of software as well as diagnose failed analysis runs, often resulting in high management overhead compared to the total computation time (Yakneen and Waszak, 2020¹). Sarek aims to minimize the installation and management time overhead by building a NGS workflow on top of Nextflow, automatically installing the required software components. These software consist of some of the state-of-the-art tools in read mapping, variant calling and annotation and quality control. Sarek is a welcome addition to the toolkit of bioinformaticians looking for an NGS analysis workflow, which can be easily installed on a HPC cluster or cloud environment. The article is well-written and clear to understand. While I'm happy to recommend indexing of the manuscript also in the present form, I have a few suggestions how to improve it:

Major comments:

1. While some of the existing NGS workflows are mentioned, I would appreciate it if

Sarek was compared to these approaches in more detail. Is there functionality that is currently missing from Sarek that is present in one of the other workflows?

This is a relevant comment, but a detailed comparison of the current functionality of different workflows risk being quickly outdated as functionality will frequently change both in Sarek and in the other mentioned workflows. Also, the main purpose of Sarek is not to provide unique functionality *per se*, but to provide a workflow solution with some generally important features as detailed in the manuscript “..(i) easy installation, (ii) robust portability across different compute environments, (iii) comprehensive documentation, (iv) transparent and easy-to-read code, and (v) extensive quality metrics reporting.”

Therefore, the main difference between Sarek and the other mentioned workflows is in practical usability rather than a particular functionality, as these can typically be tuned or added as needed.

1. Typically in NGS data analysis, a lot of time can be spent on debugging failed runs to find out whether one of the tools failed, if the data is corrupted/missing or if there was a hardware error. How does Sarek support run diagnostics and relaunching failed jobs?

This is a good comment, and NextFlow reports the failed process and the error-code from the underlying software, and Sarek is designed to make it very easy to resume failed jobs from the point of failure. This has now been better highlighted in the manuscript under the heading “Portability and reproducibility”. We will work continuously with the user community to further avoid run failures and to continuously improve the diagnostic capability and error-handling.

1. How does Sarek combine variant calls when multiple callers are used for a variant type?

Sarek will report variants from all callers include in the run, but it is up to the user to decide on how to combine results from different callers, since e.g. the optimal balance between high specificity *versus* high sensitivity differs across research projects. This has been clarified in the manuscript under the heading “Output”, and in the “Discussion”.

1. Somatic single nucleotide and indel variant calls from Sarek were shown to match well with a previously defined gold standard callset. No benchmark data was available for more complex somatic variants and variant calling accuracy for germline variants was not evaluated. I am interested in seeing more comprehensive tests to cover all germline and somatic variant types.

This is a good suggestion and we have run germline variant calling with Sarek on the HG001 sample and compared to the Genome In a Bottle gold standard dataset, and these results are now included in the manuscript.

Benchmarking of complex somatic variants is very complex and difficult due to the lack of robust and relevant benchmark datasets making such testing beyond the scope of this publications, since Sarek is a workflow and does not provide any novel algorithms or methodology *per se*. For now, we refer users to the tests published along with the respective included variant calling software. This limitation is stated in the manuscript under the heading “Results”.

1. I would appreciate it if a minimal test dataset together with instructions and a suite of automated tests was provided with Sarek. This would make it easier for the user to

test out an installation as well as raising issues in GitHub.

This is a good suggestion, and there is actually already a minimal test dataset and a suit of tests available and documented in Sarek, as detailed under the heading "Installation and testing". We have improved the Sarek documentation to make this clear and easy to find.

Minor comments:

1. How easy it is for users to modify or extend Sarek by for example adding a new variant caller to the workflow? This could be explored in more detail in text.

This is a good suggestion and we have clarified this point in the manuscript under the heading "Operation: Workflow overview and software". In brief, we have started with software we have judged being of high quality, well-maintained and robust. Additional software will be added to Sarek later on in a community effort, and this process is already ongoing.

1. It would be good to easily see which tools are used to call and analyze each variant type. This information could be added either to Fig 1, Table 1 or both.

This is a good suggestion and we have added this information to Table 1.

1. FreeBayes is included in Figure 1 but missing from Table 1.

This is a good note, and we have adjusted the manuscript accordingly. FreeBayes can optionally be run in Sarek, and it is now included in Table 1.

1. The wording in "To facilitate easy installation and to ensure reproducibility, all Sarek required tools are managed in Docker or Singularity (Kurtzer et al., 2017) containers, or a Conda environment." should be clarified -- are all tools being maintained in all the three systems?

This is a very useful comment, and this has now been clarified in the manuscript under the heading "Portability and reproducibility". All tools are installed in Conda, and then pushed to DockerHub (<https://hub.docker.com/>). This way all tools are available directly from all three systems; Conda, Docker and Singularity.

1. When running Sarek with default options, it crashes in the tool version check. It took me a while to figure out this was due to the default "-profile" argument of "standard" which seems to assume Singularity is available. It would be good to improve error messages so that it is easier to understand the underlying cause. A minimal installation and testing procedure mentioned above would help in this regard.

This is a very useful comment, and we have improved the error message and the documentation regarding the "-profile" arguments.

1. Typo: "Whole-genome sequencing (WGS) and whole-exome sequencing (WES) technologies opens..." -> "...open".

This typo has been corrected in the manuscript.

- Is the rationale for developing the new software tool clearly explained?

Yes

- Is the description of the software tool technically sound?

Yes

- Are sufficient details of the code, methods and analysis (if applicable) provided to allow replication of the software development and its use by others?
Yes
- Is sufficient information provided to allow interpretation of the expected output datasets and any results generated using the tool?
Yes
- Are the conclusions about the tool and its performance adequately supported by the findings presented in the article?
Yes

Competing Interests: No competing interests were disclosed.

Reviewer Report 09 March 2020

<https://doi.org/10.5256/f1000research.18214.r59295>

© 2020 Håndstad T. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Tony Håndstad

Oslo University Hospital, Oslo, Norway

Sarek is a workflow for variant detection and analysis of sequencing data from WGS, WES and targeted panels. The workflow is comprehensive and versatile, allowing for variant detection in both germline and somatic samples, from WGS/WES/panel sequencing.

- It includes variant calling of SNPs, indels, and structural variants, as well as annotation and extensive quality control.
- Sarek is open source and part of the nf-core community effort which builds well-curated analysis pipelines in the Nextflow pipeline framework.
- Sarek is very user friendly, and installation, configuration and execution is easy to perform, while the workflow is also flexible.
- Implementation manages to be clear, despite also being advanced with parallelization and ample choice of installation/execution. Many researchers would likely struggle to implement pipelines at this advanced level.
- The documentation is excellent, and despite the comprehensive functionality, most users should find it easy to set up Sarek and get started. I have no doubt that Sarek will be a very valuable addition to the research community.

The paper is well written and fulfils all the reviewer criteria. As reviewer, I have only a few minor comments:

- Sarek can use different Nextflow configuration profiles. In the Sarek documentation, it says that the test profile is a profile with a complete configuration for automated testing and that it includes links to test data so needs no other parameters.

It should be obvious to most users, but I would suggest that the authors make it clear that when using the test profile, a user must also supply conda, docker or singularity profile if not all the tools are installed in the PATH. This is clear from the general nf-core documentation (<https://nf-co.re/usage/introduction>) but less so from the Sarek documentation.

- Whereas the choice of Nextflow is justified, there is little argumentation for why the different tools (variant callers in particular) are selected other than that they represent state-of-the-art. Also why several tools for variant calling are combined is not mentioned, though the referred paper (Alioto *et al.*, 2015) makes a clear case for this, at least for somatic variant calling.
- The paper title makes it clear that Sarek is for whole genome sequencing analysis, but as stated in the text, Sarek is also applicable to exome and targeted panel analyses where the authors say it has been run successfully.

Many researchers are using exome sequencing, so it could be of interest to know if the authors have an opinion or experience with how use of targeted sequencing data limit Sarek in terms of accuracy or utility, for example, are the tools used for structural variant calling able to handle exome data well (to the extent possible with targeted sequencing?)

The documentation has a small chapter stating that the authors recommend supplying a BED file with the targeted regions, but there is not so much explanation of what the effect of this is.

- The authors demonstrate that Sarek is both fast and accurate by running it on a tumor/normal(germline) dataset from a previous benchmark study. I think this is acceptable/sufficient, but one could always wish for more; the paper could be strengthened by for example running the well-known public germline HG001 sample against the Genome In a Bottle gold standard dataset.
- Accurate somatic variant calling is difficult. But the included benchmark study demonstrates that Sarek performs well in comparison with other pipelines. The tool leaves it up to the user to decide whether to use output from a single variant caller or the union or intersection from all tools for increased sensitivity or precision.
- In summary, I think Sarek is a great addition to the community and recommend the paper for indexing.

Is the rationale for developing the new software tool clearly explained?

Yes

Is the description of the software tool technically sound?

Yes

Are sufficient details of the code, methods and analysis (if applicable) provided to allow replication of the software development and its use by others?

Yes

Is sufficient information provided to allow interpretation of the expected output datasets and any results generated using the tool?

Yes

Are the conclusions about the tool and its performance adequately supported by the findings presented in the article?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Diagnostic bioinformatics (variant calling pipelines) and variant interpretation

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 01 Jul 2020

Björn Nystedt, National Bioinformatics Infrastructure Sweden, Science for Life Laboratory, Uppsala University, Husargatan 3, Uppsala, Sweden

We are grateful to the reviewer for the positive and constructive comments! We have uploaded a revised version of the manuscript and included updated documentation for the workflow, including adjustments and improvements as suggested by the reviewer, and as described in the detailed comments below, marked in bold.

Approved

Sarek is a workflow for variant detection and analysis of sequencing data from WGS, WES and targeted panels. The workflow is comprehensive and versatile, allowing for variant detection in both germline and somatic samples, from WGS/WES/panel sequencing.

- It includes variant calling of SNPs, indels, and structural variants, as well as annotation and extensive quality control.
- Sarek is open source and part of the nf-core community effort which builds well-curated analysis pipelines in the Nextflow pipeline framework.
- Sarek is very user friendly, and installation, configuration and execution is easy to perform, while the workflow is also flexible.
- Implementation manages to be clear, despite also being advanced with parallelization and ample choice of installation/execution. Many researchers would

likely struggle to implement pipelines at this advanced level.

- The documentation is excellent, and despite the comprehensive functionality, most users should find it easy to set up Sarek and get started. I have no doubt that Sarek will be a very valuable addition to the research community.

The paper is well written and fulfils all the reviewer criteria. As reviewer, I have only a few minor comments:

- Sarek can use different Nextflow configuration profiles. In the Sarek documentation, it says that the test profile is a profile with a complete configuration for automated testing and that it includes links to test data so needs no other parameters.

It should be obvious to most users, but I would suggest that the authors make it clear that when using the test profile, a user must also supply conda, docker or singularity profile if not all the tools are installed in the PATH. This is clear from the general nf-core documentation (<https://nf-co.re/usage/introduction>) but less so from the Sarek documentation.

This is a good suggestion and we have highlighted and improved this information in the Sarek documentation. We are also working to revise the general documentation format in nf-core to make this more transparent throughout.

- Whereas the choice of Nextflow is justified, there is little argumentation for why the different tools (variant callers in particular) are selected other than that they represent state-of-the-art. Also why several tools for variant calling are combined is not mentioned, though the referred paper (Alioto *et al.*, 2015) makes a clear case for this, at least for somatic variant calling.

This is a good suggestion and we have clarified this point in the manuscript. In brief, we have included software we have judged being of high quality, well-maintained and robust. Additional software will be added to Sarek later on in a community effort, and this process is already ongoing.

- The paper title makes it clear that Sarek is for whole genome sequencing analysis, but as stated in the text, Sarek is also applicable to exome and targeted panel analyses where the authors say it has been run successfully.

Many researchers are using exome sequencing, so it could be of interest to know if the authors have an opinion or experience with how use of targeted sequencing data limit Sarek in terms of accuracy or utility, for example, are the tools used for structural variant calling able to handle exome data well (to the extent possible with targeted sequencing?)

The documentation has a small chapter stating that the authors recommend supplying a BED file with the targeted regions, but there is not so much explanation of what the effect of this is.

This is a relevant comment, and we want to clarify that Sarek has been run on whole-exome sequencing data in pilot user projects, and has been reported to us to work well (personal communication), but no comprehensive benchmark has been performed by us to evaluate this. This has been clarified in the Sarek documentation and in the manuscript.

- The authors demonstrate that Sarek is both fast and accurate by running it on a tumor/normal(germline) dataset from a previous benchmark study. I think this is acceptable/sufficient, but one could always wish for more; the paper could be strengthened by for example running the well-known public germline HG001 sample against the Genome In a Bottle gold standard dataset.

This is a good suggestion and we have run germline variant calling with Sarek on the HG001 sample and compared to the Genome In a Bottle gold standard dataset, and these results are now included in the manuscript.

- Accurate somatic variant calling is difficult. But the included benchmark study demonstrates that Sarek performs well in comparison with other pipelines. The tool leaves it up to the user to decide whether to use output from a single variant caller or the union or intersection from all tools for increased sensitivity or precision.
- In summary, I think Sarek is a great addition to the community and recommend the paper for indexing.
- Is the rationale for developing the new software tool clearly explained?

Yes

- Is the description of the software tool technically sound?

Yes

- Are sufficient details of the code, methods and analysis (if applicable) provided to allow replication of the software development and its use by others?

Yes

- Is sufficient information provided to allow interpretation of the expected output datasets and any results generated using the tool?

Yes

- Are the conclusions about the tool and its performance adequately supported by the findings presented in the article?

Yes

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research